微量白蛋白尿和DR患者GFR下降最快。
Patients with microalbuminuria and DR showed the fastest GFR decline.
所以我们是在病人中观察新发生的微量白蛋白尿。
So we were looking at the developments of new microalbuminuria in these patients.
结论微量白蛋白尿的测定可用于监测、防治糖尿病性心脏病。
Conclusions The menstruations of micro albumin urine can be applied to the prevention of diabetic heart disease.
微量白蛋白尿组发生联合终点事件的机率较正常UACR组高43%。
Patients with microalbuminuria were 43 percent more likely to reach the combined end point than those with normal UACR.
糖尿病患者尿中白蛋白水平增加，微量白蛋白尿是糖尿病肾病的早期表现。
An increased level of albumin in the urine of people with diabetes is an early sign of kidney damage.
目前正在进行观察性随访研究，以进一步了解预防微量白蛋白尿的长期益处。
An observational follow-up study is underway to further understand the long-term benefits of microalbuminuria prevention.
目的研究高血压患者脉压与尿白蛋白排泄率及微量白蛋白尿阳性率的关系。
Objective: To investigate the relationship between pulse pressure (PP) and urinary albumin excretion(UAE) and microalbuminuria (Malb) in patients with essential hypertension.
但之后统计的数据均提示，奥美沙坦组出现微量白蛋白尿的患者少于安慰剂组。
For the remainder of the study, fewer patients in the olmesartan group experienced microalbuminuria, compared with patients in the placebo group.
这意味着与安慰剂组相比，奥美沙坦组出现微量白蛋白尿的风险降低了23%。
This translated into a risk reduction of 23% for the olmesartan group, compared with the placebo group.
目的观察在微量白蛋白尿发生前后应用氯沙坦对糖尿病肾病(DN)的治疗作用及其机制。
Objective To estimate the therapeutical effect and mechanism of losartan on diabetic nephropathy (DN) before and after microalbuminuria.
目的：研究急性脑梗死患者微量白蛋白尿的发生率、与脑卒中危险因素及脑梗死复发的关系。
OBJECTIVE: to investigate the relationship between the incidence of MAU in patients with acute cerebral infarction and the risk factor of stroke and the recurrence of cerebral infarction.
目的探讨微量白蛋白尿(MA)与非糖尿病急性心肌梗死(NDM AMI)患者预后的关系。
Objective To investigate prognostic significance of microalbuminuria (MA) in non-diabetic acute myocardial infarction (NDM-AMI) patients.
此外，ROADMAP数据证明奥美沙坦可预防2型糖尿病患者发生微量白蛋白尿(mau)。
In addition, data from ROADMAP proved that olmesartan can reduce risk of microalbuminuria (MAU) in Type 2 diabetes (T2DM) patients.
目的研究急性脑梗死患者微量白蛋白尿(mau)的发生率、与卒中危险因素及脑梗死复发的关系。
Objective to assess the prevalence of microalbuminuria (MAU) in patients with recent cerebral infarction and its associations to risk factors for stroke and recurrence.
结论普伐他汀可改善代谢综合征患者的血脂紊乱、高血压及微量白蛋白尿，可安全地应用于代谢综合征患者。
Conclusion Pravastatin can be safely used for treating metabolic syndrome because it can ameliorate the lipid disturbance, hypertension and microalbuminuria.
本研究以糖尿病患者出现肾损害的最初临床表现——微量白蛋白尿的出现比率作为标准，进行各组间的比较。
Rates of microalbuminuria-small amounts of the protein albumin in urine, the first sign of diabetic kidney disease-were compared between groups.
微量白蛋白尿是糖尿病肾病发病的首要指征，也是早期出现心血管疾病的重要指征之一，可提示微血管病变。
Microalbuminuria is the first sign of the pathogenesis of diabetic nephropathy. It is also an important marker of early development of cardiovascular disease and can indicate microvascular disease.
至于微量白蛋白尿与胰岛素抵抗有直接的病理生理联系，还是仅与该综合征的某些代谢紊乱有关，目前尚不清楚。
It is still unclear whether microalbuminuria is directly associated with insulin resistance in pathophysiology or it is merely related...
多数糖尿病患者起病后6～15年开始出现微量白蛋白尿，10～15年后进入显性蛋白尿期，出现大量蛋白尿。
Most diabetic patients began to have microalbuminuria after 6 to 15 years when they were diagnosed diabetes, 10 to 15 years later they went into a period of large volume proteinuria.
经过糖化血色素，胰岛素使用，微量白蛋白尿，心血管疾病和抑郁评分模型中的夹杂物，每一个有显着相关的预期寿命。
After inclusion of A1C, insulin use, microalbuminuria, cardiovascular disease, and depression scores in the model, each was significantly related to life expectancy.
对患有微量白蛋白尿的2型糖尿病患者的深度多因素临床干预几乎阻止了糖尿病蛋白尿的进展，但却能改变GF R减低的结局。
Intensive multifactorial intervention in patients with type 2 diabetes with microalbuminuria nearly halved the progression of proteinuria but did not alter the rate of GFR decline.
您很容易在7或8年内进展到微量白蛋白尿……但是已经有巨量蛋白尿的患者，则进展率极低”博士Czupryniak指出。
You can progress within 7 or 8 years to microalbuminuria very easily… but people who already had macroalbuminuria, then the progression rate was very, very low, " Dr."
结论：在正常白蛋白尿和低微量白蛋白尿的日本2型糖尿病患者中，基线有微量白蛋白尿与8年内大量白蛋白尿风险升高具有相关性。
CONCLUSIONS:In normo- and low microalbuminuric Japanese type 2 diabetic patients, presence of microalbuminuria at baseline was associated with higher risk of macroalbuminuria in 8 years.
在进行了眼底检查的患者中，视网膜病变的患病率为57.9%，在进行了尿微量白蛋白筛查的患者中，微量白蛋白尿的患病率为49.0%。
Among the diabetic patients who had examined the eyeground or screened the microalbuminuria, the ratios of diabetic retinopathy and microalbuminuria were 57.9%, 49.0% respectively.
Bilou教授：根据我们现有的数据，就像今天汇报的那样，还不能说坎地沙坦（Candesatan）对微量白蛋白尿的一级预防是有用的。
Prof. R. W. Bilou: Well, at the moment from our data as presented today we can't say that Candesatan has a role for the primary prevention of microalbuminuria.
巨量白蛋白尿的患者组，其肾病进展的危险因素与微量白蛋白尿组相似，其进展的患者肾小球滤过率较低（GFRs）且诊断有心血管疾病或心力衰竭。
The macroalbuminuria group had risk factors similar to the microalbuminuria group, and had lower glomerular filtration rates (GFRs) and a diagnosis of cardiovascular disease or heart failure.
我们研究了使用血管紧张素受体阻断剂（ARB）进行治疗是否能延缓或预防尿白蛋白正常的2型糖尿病患者出现微量蛋白尿。
We investigated whether treatment with an angiotensin-receptor blocker (ARB) would delay or prevent the occurrence of microalbuminuria in patients with type 2 diabetes and normoalbuminuria.
我们研究了使用血管紧张素受体阻断剂（ARB）进行治疗是否能延缓或预防尿白蛋白正常的2型糖尿病患者出现微量蛋白尿。
We investigated whether treatment with an angiotensin-receptor blocker (ARB) would delay or prevent the occurrence of microalbuminuria in patients with type 2 diabetes and normoalbuminuria.
应用推荐